Xeris Swings to $11.3M Third-Quarter Profit
XERS sits 100% above its 52-week low of $5.25.
Summary
Xeris posted third-quarter net income of $11.3 million, a swing to profit from the $31.1 million net loss reported in Q2, when a $30.8 million non-cash debt extinguishment charge drove the red ink. Third-quarter EPS came in at 6c. The headline gives only the bottom line, so revenue and the durability of the profit are not yet clear from this item. The turn matters because the prior quarter's loss was largely accounting-driven, and a clean profit would confirm the Recorlev-led revenue growth is carrying through. The company also has a Phase 3 readout pending for XP-8121, its once-weekly subcutaneous levothyroxine, with topline data expected.
At the time of this announcement, XERS was trading at $10.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.25 to $11.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.